5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.

CONCLUSIONS: A response to Aza is not associated with eradication of malignant clones, but rather with a stabilization of the clonal architecture. We suggest changes in CpG methylation levels of EZH2 and NOTCH1 as potential targets of epigenetic response to Aza treatment which may also serve as useful biomarkers after clinical evaluation. PMID: 31506740 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31506740?dopt=Abstract

Source: Clin Med Res - September 9, 2019 Category: Research Authors: Gawlitza AL, Speith J, Rinke J, Sajzew R, Müller EK, Schäfer V, Hochhaus A, Ernst T Tags: J Cancer Res Clin Oncol Source Type: research